Trials / Completed
CompletedNCT01104792
Long-term Study of Cariprazine in Patients With Schizophrenia
Evaluation of the Long-term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 752 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cariprazine | Cariprazine was supplied in capsules. |
Timeline
- Start date
- 2010-05-31
- Primary completion
- 2013-01-31
- Completion
- 2013-01-31
- First posted
- 2010-04-15
- Last updated
- 2019-07-26
- Results posted
- 2019-07-26
Locations
86 sites across 6 countries: United States, Colombia, India, Romania, Russia, Ukraine
Source: ClinicalTrials.gov record NCT01104792. Inclusion in this directory is not an endorsement.